DOXORUBICIN HYDROCHLORIDE
Generic: DOXORUBICIN HYDROCHLORIDE
Actavis PharmaManufacturer
INTRAVENOUSRoute
DOXORUBICIN HYDROCHLORIDEActive Substance
2014-06-27Original Approval
DOXORUBICIN HYDROCHLORIDE is FDA application ANDA203622, sponsored by ACTAVIS INC. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class III2020-11-17
DOXOrubicin Hydrochloride Injection, USP, 10 mg / 5 mL (2 mg / mL), 5 mL fill in a 6 mL vial, Single Dose Vial, Rx only,Cross Contamination with Other Products: trace amounts of octreotide found during testing
Class I2026-05-12
DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL (2mg/mL), 25 mL single-dose vials, Sterile, Rx only, ManufacturePresence of Particulate matter: Particulate matter identified as glass.
Class II2018-01-16
DOXOrubicin Hydrochloride Liposome Injection, 20 mg/10 ml (2 mg/mL), 10 mL Single Use Vial, Distributed by: Sun PharmaceLack Of Assurance Of Sterility
Top Reported Reactions
1
FEBRILE NEUTROPENIA
9,350 reports
2
OFF LABEL USE
9,070 reports
3
DISEASE PROGRESSION
6,616 reports
4
NEUTROPENIA
6,568 reports
5
DRUG INEFFECTIVE
5,306 reports
6
PYREXIA
4,154 reports
7
ANAEMIA
3,896 reports
8
THROMBOCYTOPENIA
3,888 reports
9
NAUSEA
3,239 reports
10
DEATH
3,157 reports